TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35545412
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 μg/(kg·h) (Dex2 group)
Study: 33217839
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion therapy (3 times a week for 3 menstrual cycles)
Study: 33217839
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion therapy
Study: 32574587
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dupilumab every 4 weeks + medium-potency topical corticosteroids (TCS)
Study: 32230954
Drug: Leucine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (6 g/day)
Study: 37887975
Drug: Placebo (lactose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose, 6 g/day)
Study: 34666412
Drug: Capsiate (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsiate (12 mg)
Study: 34666412
Drug: Placebo (starch:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch: 12 mg)
Study: 33932162
Drug: Nicotine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (6 mg) administered to cannabis users (CU)
Study: 33932162
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to cannabis users (CU)
Study: 33516285
Drug: Lumacaftor-ivacaftor therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor-ivacaftor therapy
Study: 33516285
Drug: Placebo to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to treatment group
Study: 32043288
Drug: saxagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin (5 mg/day) plus conventional therapy
Study: 32043288
Drug: vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D3 (2000 IU/day) plus saxagliptin and conventional therapy
Study: 32043288
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional therapy with metformin (1-1.7 g/day) and/or insulin treatment
Study: 35001410
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training + placebo (CT)
Study: 35001410
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training + saffron supplementation (CTS)
Study: 33351194
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy at 2 l.kg-1.min-1
Study: 33351194
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal therapy at 4 l.kg-1.min-1
Study: 32527329
Drug: Skin cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin cancer preventive behaviors (wearing sun-blocking clothing, using sunscreen cream, wearing a cap, using gloves and sunglasses)
Study: 34259408
Drug: Chinese medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medication
Study: 32470923
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (70-ml, containing ∼4.1 mmol of nitrate)
Study: 32470923
Drug: Placebo (70-ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (70-ml, containing ∼0.04 mmol of nitrate)
Study: 33297409
Drug: Chlorogenic acids
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acids (CGAs) 270 mg tablets
Study: 33790860
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide or lanreotide monotherapy for ≥4 months
Study: 32006087
Drug: Ethosuximide (500,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethosuximide (500, 1000, or 1500 mg)
Study: 32006087
Drug: Ethosuximide (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethosuximide (1500 mg/day)
Study: 33259935
Drug: Palliative Volumetric
Normalized name: SETS,VOLUMETRIC,INTRAVENOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative Volumetric Arc Therapy (VMAT)
Study: 33259935
Drug: 3-Dimensional Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-Dimensional Conventional Radiation Therapy (3DCRT)
Study: 32248594
Drug: Pilocarpine (1.54%)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (1.54%) spray, used three times a day for 3 months
Study: 32248594
Drug: Pilocarpine (1.54%)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (1.54%) spray
Study: 33721085
Drug: Structured skills
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured skills training group (SSTG) based on dialectical behavioural therapy
Study: 32108382
Drug: Skin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin patches of Xin Huang Pian
Study: 34844893
Drug: Corticosteroid (CS;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (CS; cortivazol) injection
Study: 32576219
Drug: SD-101 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 6% cream
Study: 34379946
Drug: Proprietary combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen)
Study: 34378307
Drug: BAX‐HI (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX‐HI (1 U/mL)
Study: 34378307
Drug: NOVO‐HI (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOVO‐HI (100 U/mL diluted to 1 U/mL)
Study: 34890532
Drug: 12-week supervised
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week supervised exercise training programme (moderate intensity combination aerobic/resistance exercise training programme)
Study: 36399379
Drug: Automated virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated virtual reality cognitive therapy (gameChange)
Study: 35396311
Drug: CKD-related video
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-related video decision aid followed by recording personal video declarations about goals of care and treatment preferences
Study: 32885568
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (2 g combined probiotics daily)
Study: 32308074
Drug: LED irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LED irradiation for 24 sessions (3 sessions per week) in addition to standard medical treatment
Study: 32308074
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment for 8 weeks
Study: 35943252
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 600 mg daily (fixed dosing)
Study: 35943252
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing (10 mg/kg)
Study: 35943252
Drug: Rifapentine and
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine and isoniazid regimen (1-month daily)
Study: 34629430
Drug: Curettage +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curettage + platelet-rich plasma gel
Study: 33932461
Drug: Diving method
Normalized name: Eucalyptus dives leafy twig oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diving method (500 mL of water administered every hour when the capsule reached the small bowel)
Study: 35066365
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based transdiagnostic individually tailored Cognitive Behavioral Therapy (iCBT)
Study: 32701116
Drug: Febuxostat 20
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 20 mg
Study: 35431205
Drug: Customized on-site
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized on-site exercise program including manual and exercise therapy from physiotherapy
Study: 34411745
Drug: Intensive patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive patient education (two, one-hour treatment sessions)
Study: 34411745
Drug: Placebo patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patient education (two, one-hour treatment sessions)
Study: 35965825
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1.5 mg/kg lidocaine 10 minutes prior to induction, followed by 2 mg/kg/h until the end of surgery)
Study: 34967575
Drug: Kali Haldi
Normalized name: Salsola kali pollen
DrugBank: Salsola kali pollen (DB10388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kali Haldi and aloe vera gel mixture, 3 times a day for 3 months
Study: 34967575
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of hydrocortisone and hyaluronidase for 6 weeks with oral antioxidant supplements for 3 months
Study: 32683644
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 50 mg
Study: 35636802
Drug: elobixibat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: elobixibat (10 mg)
Study: 33844469
Drug: Temozolomide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (150 mg/m2/day PO on days 1–5) and Irinotecan (50 mg/m2/day IV on days 1–5) plus Bevacizumab (10 mg/kg IV on days 1 and 15)
Study: 33844469
Drug: Temozolomide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (150 mg/m2/day PO on days 1–5) and Irinotecan (50 mg/m2/day IV on days 1–5)
Study: 32960632
Drug: Low glycaemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycaemic index preparations
Study: 34227397
Drug: >0% to
Approvals — FDA: no, EMA: no, PMDA: no
Description: >0% to 12.5% beta-blocker dose
Study: 34227397
Drug: >25% to
Approvals — FDA: no, EMA: no, PMDA: no
Description: >25% to 50% beta-blocker dose
Study: 34227397
Drug: >12.5% to
Approvals — FDA: no, EMA: no, PMDA: no
Description: >12.5% to 25% beta-blocker dose
Study: 34227397
Drug: Full-dose beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose beta-blocker
Study: 35708758
Drug: Targeted antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antifungal therapy driven by culture results (Control)
Study: 32108122
Drug: Oral 50
Normalized name: fat supplement, oral 50% oral emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 50 mg tramadol
Study: 34748549
Drug: Cognition-Targeted Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition-Targeted Exercise (CTE) with Cognitive Behavior Therapy (CBT)
Study: 34748549
Drug: Symptom-Targeted Exercise
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-Targeted Exercise (STE) with Cognitive Behavior Therapy (CBT)
Study: 35639197
Drug: Siponimod (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod (2 mg/day)
Study: 36498624
Drug: Polaprezinc-containing therapy
Normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc-containing therapy (PQT)
Study: 36498624
Drug: Bismuth-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing therapy (BQT)
Study: 34826381
Drug: CVnCoV (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVnCoV (12 μg of mRNA, two 0.6 mL doses, days 1 and 29)
Study: 34826381
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl, two 0.6 mL doses, days 1 and 29)
Study: 32133780
Drug: Aspirin 150
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 150 mg oral daily from the first trimester
Study: 33603941
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA) with remifentanil and propofol (n = 35)
Study: 35078079
Drug: Partial-oral treatment
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial-oral treatment
Study: 38734138
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment
Study: 36050653
Drug: Nivolumab after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab after temozolomide treatment
Study: 32088302
Drug: Granulocyte Colony-Stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte Colony-Stimulating Factor (G‐CSF) administered for 5 days every 3 months for 4 cycles (group A, n = 50)
Study: 32088302
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone (group B, n = 50)
Study: 35972531
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg of caffeine
Study: 34151724
Drug: internet-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based Cognitive Behavioral Therapy (iCBT)
Study: 35403350
Drug: Exenatide XR
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide XR 2.0 mg weekly
Study: 33291700
Drug: Chili (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chili (2 g)
Study: 37531986
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% bupivacaine
Study: 34686616
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (noncaloric juice)
Study: 33320868
Drug: Positive-control (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive-control (140 ml of water)
Study: 33320868
Drug: Placebo-trial (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-trial (140 ml NO3‐ depleted beetroot juice)
Study: 33320868
Drug: Negative-control (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-control (140 ml of water)
Study: 35388235
Drug: Nebulized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized lidocaine 1.0 mg/kg body weight (BW), q12h for 14 days
Study: 35388235
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide 1 μg/kg, q12h for 14 days
Study: 35028769
Drug: VS+PBMT (vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS+PBMT (vaginal stretching combined with photobiomodulation therapy)
Study: 35028769
Drug: VS+shamPBMT (vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS+shamPBMT (vaginal stretching combined with sham photobiomodulation therapy)
Study: 33575340
Drug: Hospital-based systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based systemic rehabilitation (50-minute sessions, three times weekly for 12 weeks)
Study: 32292360
Drug: Drug plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug plus psychotherapy (DPP) - olanzapine and metacognitive training
Study: 32292360
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (DT) - olanzapine only
Study: 34510258
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with surgery (22%)
Study: 34510258
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (80% completed treatment with curative intent)
Study: 34897226
Drug: Oral Naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Naltrexone (NTX)
Study: 32330571
Drug: Riboflavin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (1.6 mg/d) for 16 weeks, n=24
Study: 36249252
Drug: Cansino vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cansino vaccine
Study: 36249252
Drug: Sinovac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac vaccine
Study: 32167792
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2100 mg/day)
Study: 33392664
Drug: HEMOCIN® patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEMOCIN® patch
Study: 33392664
Drug: No systematic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systematic treatment (control)
Study: 36684501
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 300 mg/day
Study: 36123783
Drug: EMP16-120/40 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMP16-120/40 (120 mg orlistat/40 mg acarbose)
Study: 36123783
Drug: EMP16-150/50 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMP16-150/50 (150 mg orlistat/50 mg acarbose)
Study: 34748059
Drug: Intratumoral (IT)
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral (IT) tracer injection (2 depots of 1 mL indocyanine green-[99mTc]Tc-nanocolloid)
Study: 34748059
Drug: Intraprostatic (IP)
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic (IP) tracer injection (4 depots of 0.5 mL indocyanine green-[99mTc]Tc-nanocolloid)
Study: 32367880
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave therapy (ESWT) once a week for 3 weeks
Study: 32150855
Drug: UVB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB group (half‐body UVB irradiation, twice weekly over 6 months, with 1 standard erythema dose (SED))
Study: 35973626
Drug: Local prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local prophylactic antibiotic therapy with vancomycin loaded calcium sulfate beads
Study: 33862000
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), followed by chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 or capecitabine).
Study: 33862000
Drug: Standard-of-care (chemoradiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy for 6 months).
Study: 33862000
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (during neoadjuvant chemotherapy).
Study: 33862000
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (during adjuvant chemotherapy).
Study: 33862000
Drug: Standard-of-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care group (during adjuvant chemotherapy).
Study: 33862000
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (serious adverse events during the whole treatment period).
Study: 33862000
Drug: Standard-of-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care group (serious adverse events during the whole treatment period).
Study: 33862000
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (serious adverse events during adjuvant therapy).
Study: 33862000
Drug: Standard-of-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care group (serious adverse events during adjuvant therapy).
Study: 33862000
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (treatment-related deaths).
Study: 33862000
Drug: Standard-of-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care group (treatment-related deaths).
Study: 34273650
Drug: Black chokeberry
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black chokeberry dried pomace (30 g/kg of feed)
Study: 34273650
Drug: Black currant
Normalized name: Black currant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black currant dried pomace (30 g/kg of feed)
Study: 34273650
Drug: Raspberry dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raspberry dried pomace (30 g/kg of feed)
Study: 39557730
Drug: Peptide receptor
Normalized name: Polypeptide receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide receptor radionuclide therapy (PRRT)
Study: 32078815
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mL of 0.9% saline)
Study: 35661378
Drug: TTP399 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTP399 (800 mg)
Study: 32580838
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 30-minute intervals with a pulse dose of 5 mL (Group A)
Study: 32580838
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 60-minute intervals with a pulse dose of 10 mL (Group B)
Study: 34726317
Drug: Continuous low-energy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low-energy diet (CLED) - 8 weeks/56 days of daily Optifast 820 kcal (3430 kJ) diet
Study: 34460933
Drug: GOP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GOP infusion (n = 14)
Study: 32294346
Drug: SEP‐363856 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP‐363856 (50 mg or 75 mg)
Study: 35349757
Drug: No ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No ganciclovir treatment (Control)
Study: 35739147
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVA) monotherapy
Study: 35739147
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVA) + subthreshold laser (SL) combination therapy
Study: 32686217
Drug: Tested preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tested preparation